Clinical trial NCT03531450: Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
Official title: Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gastroparesis
Keywords: Gastroparesis
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2018-05-21
Enrollment: 29
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-center pilot study to be conducted at Massachusetts General Hospital. The purpose of this study is to examine the non-pharmacological impact of Cognitive Behavioral Therapy (CBT) on gastroparesis symptoms and other clinical co-comorbidities such as pain, depression, anxiety, and catastrophizing. CBT trial patients will undergo careful phenotyping pre- and post- intervention with brain MRI, autonomic function test (AFT), gastric emptying scintigraphy (GES), and nutrient drink test (NDT) to determine the impact of CBT on these metrics in patients with gastroparesis. Characterization of these relationships or lack thereof can help guide future development of more targeted approaches and optimize treatment strategies for gastroparesis.

Detailed description: This randomized, controlled trial will examine the effects of cognitive behavioral therapy (CBT) on gastroparesis symptoms (including pain related brain circuitry). CBT reduces pain intensity, negative affect, and disability among patients with chronic pain, though there is a good deal of individual variability in treatment effects. Treatment gains following CBT are maintained or enhanced at 6 to 12-month follow-up. This study will examine the brain circuitry underlying these effects. In addition, as measures of gastroparesis symptoms and pain are correlated with other, more general, measures of negative affect (e.g., depression, anxiety), we will evaluate the specificity of the hypothesized effects by running the proposed statistical models both with and without inclusion of these conceptually overlapping factors. Based on pervious findings and published data, we expect that treatment-associated changes in pain and depression will likely share 10-20% of their variance.

Treatment sessions will use active, structured techniques to alter distorted thoughts, with a focus on acquiring and practicing cognitive and emotional modulatory skills. CBT is based on a pain self-management paradigm, and involves the identification and reduction of maladaptive pain-related cognitions (i.e., catastrophizing) using techniques such as relaxation, thought-stopping, distraction, etc. CBT prominently emphasizes in-vivo practice during each session, and features home practice using written exercises. In particular, cognitive restructuring is used to help patients recognize the relationships between thoughts, feelings and behaviors. Patients learn to identify, evaluate, and challenge negative thoughts. In our protocol, each of the 8 weekly sessions will last for approximately 90 minutes and will be conducted or supervised by a trained psychologist. Following CBT, negative emotions are no longer closely linked to pain, suggesting that CBT provides patients with the skills to modulate and buffer their negative emotions such as catastrophizing.

Subjects will undergo pre- and post-treatment testing through a variety of methods including brain MRI with associated physiological data, autonomic function test (AFT), gastric emptying scintigraphy (GES), and nutrient drink test (NDT) to determine the impact of CBT on these metrics in patients with gastroparesis. Characterization of these relationships or lack thereof can help guide future development of more targeted approaches and optimize treatment strategies for gastroparesis.

Eligibility criteria: Inclusion Criteria:

1. Male and female patients aged 18 - 65 years old (inclusive)
2. Symptoms of gastroparesis of at least 12 weeks duration (do not have to be continuous) with varying degrees of nausea, vomiting, early satiety, and/or post-prandial fullness
3. An idiopathic etiology
4. GES of solids using 4 hours Egg Beaters® protocol within the last 2 years with either:

   - Abnormal gastric emptying rate defined as an abnormal 2 hour (\>60% retention) and/or 4 hour (\>10% retention) result based on a 4 hour scintigraphic low fat Egg Beaters® gastric emptying study.
5. Body mass index (BMI) ≥ 17.5 kg/m2
6. Have not previously received CBT for coping with chronic illness
7. Have access to a computer with internet access
8. Speak, write, and understand English
9. On stable doses of any medication for 30 days prior to entering the study (exceptions are psychotropic, opioids, and/or illicit drugs) and agrees not to change medications or dosages during the study period.

Exclusion Criteria:

1. Inability to comply with or complete GES test (including allergy to eggs)
2. Use of narcotic analgesics greater than three days per week
3. Presence of other conditions that could explain the patient's symptoms:

   * Pyloric or intestinal obstruction as determined by endoscopy, upper GI series or abdominal CT scan
   * Active inflammatory bowel disease
   * Known eosinophilic gastroenteritis or eosinophilic esophagitis
   * Primary neurological conditions that could cause nausea and/or vomiting such as increased intracranial pressure, space occupying or inflammatory/infectious lesions
   * Acute liver failure
   * Acute renal failure
   * Chronic renal failure (serum creatinine \>3 mg/dL) and/or on hemodialysis or peritoneal dialysis
   * Prior gastric surgery to restore function or relieve GI symptoms including total or subtotal (near complete) gastric resection, esophagectomy, gastrojejunostomy, or gastric bypass, gastric sleeve, pyloroplasty, pyloromyotomy. Note: patients with prior (Nissen, Dor, or Toupet) fundoplication will be eligible for enrollment.
   * Subject has current evidence of duodenal ulcer, gastric ulcer, diverticulitis, active GERD or infectious gastroenteritis.
   * Any acute gastrointestinal process.
   * Any other plausible structural or metabolic cause
   * Any condition, which in the opinion of the investigator, would interfere with study requirements
4. Inability to provide informed consent
5. BMI more than 32 and/or weight \> 235 lbs. (limits of the MRI table)
6. Enteral or parenteral feeding
7. Epilepsy or a prior history of seizures
8. Pregnancy or nursing
9. Psychotherapy initiated in the last 8 weeks
10. Contraindications for MRI: High magnetic fields may pose a serious health hazard to subjects with implanted ferromagnetic objects. Every subject in this study will be carefully screened before entering the high magnetic field shielded room to collect a precise outline of the subject's medical history. Subjects with the following characteristics/disease will not be eligible to participate in the study:

    * History of Head Trauma
    * Any metallic implants (e.g. braces or permanent retainers)
    * Tattoos with metallic ink above the nipple line
    * Surgical Aneurysm Clips
    * Cardiac Pacemaker
    * Prosthetic Heart Valve
    * Neurostimulator
    * Implanted pumps
    * Cochlear Implants
    * Metal rods, Plates
    * Screws
    * Recent Previous Surgery
    * IUD
    * Hearing Aid
    * Dentures (which might create NMR artifacts)
    * Metal Injury to eyes
    * Pregnancy or plans to become pregnant
    * Breast Feeding
    * Meniere's Disease
    * Transdermal (skin) patches such as NicoDerm (nicotine for tobacco dependence), Transderm Scop, or Ortho Evra (birth control)
    * Claustrophobia
    * Suicidal ideation as indicated from the HADS

All concomitant medications taken during the study will be recorded in the case report form, along with dosage information and start and stop dates. Patients requiring excluded drugs will be discontinued from the study.

Primary outcomes:
measure: Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM)
timeFrame: Up to 12 weeks
Secondary outcomes:
measure: Gastrointestinal symptom assessment via Short Form 36 Health Survey
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Patient Assessment of Upper Gastrointestinal Disorders - Quality of Life
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Rome III Diagnostic Questionnaire for Adult Functional GI Disorders
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Hospital Anxiety and Depression Scale
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Patient Health Questionnaire
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via PainDETECT
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Pain Catastrophizing Scale
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Neuropathy Total Symptoms Score
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via PTSD Questionnaire - PCL-5
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Brief Pain Inventory
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Early Life Trauma Inventory Self Report - Short Form
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Coping Strategies Questionnaire
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Pain Self-Efficacy Questionnaire
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Eysenck Personality Inventory
timeFrame: Up to 12 weeks
measure: Gastrointestinal symptom assessment via Perceived Stress Scale
timeFrame: Up to 12 weeks
measure: Structural fMRI, resting fMRI, fMRI during catastrophizing test
timeFrame: Baseline, and up to 2 hours post-intervention
measure: Multivoxel 3D Proton Resonance Spectroscopy
timeFrame: Baseline, and up to 2 hours post-intervention
measure: Autonomic Function Testing (AFT)
timeFrame: Baseline, and up to 1 hour post-intervention
measure: Abdominal Quantitative Sensory Testing (QST)
timeFrame: Baseline, and up to 1 hour post-intervention
measure: Electrogastrogram acquired during MRI scans
timeFrame: Baseline, and up to 2 hour post-intervention
measure: Electrocardiogram acquired during MRI scans
timeFrame: Baseline, and up to 2 hour post-intervention
measure: Respiration during MRI scans
timeFrame: Baseline, and up to 2 hour post-intervention
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Braden Kuo, MD
role: PRINCIPAL_INVESTIGATOR
References: